# A Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad26.RSV.FA2 Followed by Ad35.RSV.FA2 in Healthy Adult Volunteers

> **NCT02561871** · PHASE1 · COMPLETED · sponsor: **Crucell Holland BV** · enrollment: 34 (actual)

## Conditions studied

- Respiratory Syncytial Viruses
- Respiratory Tract Infections

## Interventions

- **BIOLOGICAL:** Ad26.RSV.FA2
- **BIOLOGICAL:** Ad35.RSV.FA2
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02561871
- **Lead sponsor:** Crucell Holland BV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2016-09
- **Final completion:** 2016-09
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2016-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02561871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02561871, "A Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad26.RSV.FA2 Followed by Ad35.RSV.FA2 in Healthy Adult Volunteers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02561871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*